MARÍA LUISA CAÑADAS GARRE-rekin lankidetzan egindako argitalpenak (21)

2021

  1. Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis

    Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726

2020

  1. Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis

    Pathology Research and Practice, Vol. 216, Núm. 4

  2. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma

    Surgical Oncology, Vol. 35, pp. 388-398

2019

  1. Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients

    Mutation Research - Reviews in Mutation Research, Vol. 781, pp. 63-70

  2. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

    Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177

2018

  1. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer

    Pathology Research and Practice, Vol. 214, Núm. 1, pp. 44-52

  2. Pharmacogenetic biomarkers of response in Crohn's disease

    Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 1-13

2017

  1. ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis

    Surgical Oncology, Vol. 26, Núm. 4, pp. 473-482

  2. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer

    Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58

  3. Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer

    Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444

  4. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer

    Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285

2016

  1. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients

    Pharmacological Research, Vol. 108, pp. 111-118

  2. Gene polymorphisms as predictors of response to biological therapies in psoriasis patients

    Pharmacological Research, Vol. 113, pp. 71-80

  3. Liquid biopsy in early stage lung cancer

    Translational Lung Cancer Research, Vol. 5, Núm. 5, pp. 517-524

  4. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients

    Pharmacological Research, Vol. 111, pp. 877-884

2015

  1. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer

    Pharmacogenomics, Vol. 16, Núm. 12, pp. 1411-1426

  2. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer

    Pharmacological Research, Vol. 102, pp. 90-106

  3. MET: A new promising biomarker in non-small-cell lung carcinoma

    Pharmacogenomics, Vol. 16, Núm. 6, pp. 631-647

  4. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer

    Breast Cancer Research and Treatment, Vol. 153, Núm. 3, pp. 493-505

  5. PTEN and PI3K/AKT in non-small-cell lung cancer

    Pharmacogenomics, Vol. 16, Núm. 16, pp. 1843-1862